Conatus Pharmaceuticals (CNAT) PT Lifted to $9 at Piper Jaffray Following Phase II Emricasan Data
Tweet Send to a Friend
Piper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Conatus Pharmaceuticals (NASDAQ: CNAT) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE